Loading…
LINEZOLID is a brand name for Linezolid, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ...................................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................................ 4 WARNINGS AND…
Verbatim from this product's HC label. Tap a section to expand.
General The use of antibiotics may promote the overgrowth of nonsusceptible organisms. Should superinfection occur during therapy, appropriate measures should be taken. Linezolid has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.
Large quantities of foods or beverages with high tyramine content should be avoided while taking Linezolid (see DRUG INTERACTIONS, Drug-Food Interactions for foods or beverages with high tyramine content). In healthy volunteers, co-administration of rifampin with linezolid resulted in a 21% decrease in linezolid Cmax and a 32% decrease in linezolid AUC (see DRUG INTERACTIONS, Drug-Drug Interactions, Antibiotics).
The clinical significance of this interaction is unknown. The safety and efficacy of linezolid given for longer than 28 days have not been evaluated in controlled clinical trials. Lactic acidosis Lactic acidosis has been reported with the use of linezolid.
Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving Linezolid should receive immediate medical attention. Mortality Imbalance in an Investigational Study in Patients with Catheter-Related Bloodstream Infections, including those with catheter-site infections.
5%) vs. 098]. While causality has not been established, this observed imbalance occurred primarily in linezolid-treated patients in whom either Gram-negative pathogens, mixed Gram-negative and Gram-positive pathogens, or no pathogen were identified at baseline, but was not seen in patients with Gram-positive infections only.
Linezolid is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections. Linezolid has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections.
It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected; appropriate concomitant therapy is also required when anaerobic pathogens are isolated (see INDICATIONS AND CLINICAL USE).
Serotonin Syndrome PrLinezolid (linezolid) Product Monograph Page 6 of 36 Very rare spontaneous reports of serotonin syndrome with co-administration of linezolid and serotonergic agents have been reported. , hyperpyrexia, and cognitive dysfunction) in patients receiving such concomitant therapy (see CONTRAINDICATIONS, ADVERSE REACTIONS and DRUG INTERACTIONS, Drug-Drug Interactions, Serotonergic Agents).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Linezolid in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Carcinogenesis and Mutagenesis See TOXICOLOGY, Carcinogenicity, Toxicology and Mutagenicity Endocrine and Metabolism Diabetes Some MAO inhibitors have been associated with hypoglycemic episodes in diabetic patients receiving insulin or oral hypoglycemic agents.
While a causal relationship between linezolid and hypoglycemia has not been established, diabetic patients should be cautioned of potential hypoglycemic reactions when treated with linezolid. If hypoglycemia occurs, a decrease in the dose of insulin or oral hypoglycemic agent, or discontinuation of oral hypoglycemic agent, insulin, or linezolid may be required.
Therefore, Linezolid should be used with caution in diabetics under treatment with this drug. Gastrointestinal Clostridium difficile-associated disease Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including linezolid.
CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent.
CDAD has been reported to occur over 2 months after the administration of antibacterial agents. Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth to Clostridium difficile. Clostridium difficile produces toxins A and B, which contribute to the development of CDAD.
CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy. If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against Clostridium difficile.
In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against Clostridium difficile. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases (see ADVERSE REACTIONS section).
Hematologic Myelosuppression Myelosuppression (anemia including pure red blood cell aplasia, leukopenia, pancytopenia, and PrLinezolid (linezolid) Product Monograph Page 7 of 36 thrombocytopenia) has been reported in patients receiving linezolid.
In cases where the outcome is known, when linezolid was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Complete blood counts should be monitored at least weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, patients who are at increased […]